JP2018522887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522887A5 JP2018522887A5 JP2018501155A JP2018501155A JP2018522887A5 JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5 JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hpv
- subject
- antibody according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169277A JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192396P | 2015-07-14 | 2015-07-14 | |
| US62/192,396 | 2015-07-14 | ||
| PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Division JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522887A JP2018522887A (ja) | 2018-08-16 |
| JP2018522887A5 true JP2018522887A5 (enExample) | 2019-08-22 |
Family
ID=56551000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501155A Withdrawn JP2018522887A (ja) | 2015-07-14 | 2016-07-14 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544224B2 (enExample) |
| EP (3) | EP4679094A2 (enExample) |
| JP (3) | JP2018522887A (enExample) |
| KR (2) | KR20180027576A (enExample) |
| CN (1) | CN107922502A (enExample) |
| CY (1) | CY1123993T1 (enExample) |
| DK (2) | DK3858859T3 (enExample) |
| ES (2) | ES2855798T3 (enExample) |
| FI (1) | FI3858859T3 (enExample) |
| HR (2) | HRP20210399T1 (enExample) |
| HU (1) | HUE053966T2 (enExample) |
| LT (2) | LT3322731T (enExample) |
| PL (1) | PL3322731T3 (enExample) |
| PT (2) | PT3322731T (enExample) |
| RS (2) | RS61532B1 (enExample) |
| SI (1) | SI3322731T1 (enExample) |
| SM (2) | SMT202100131T1 (enExample) |
| WO (1) | WO2017011666A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| EP3313186A4 (en) | 2015-06-29 | 2019-04-03 | Biomed Valley Discoveries, Inc. | LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| DK3858859T3 (da) | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
| MY187739A (en) | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN108350081A (zh) * | 2015-11-18 | 2018-07-31 | 百时美施贵宝公司 | 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌 |
| KR20180094977A (ko) * | 2015-12-17 | 2018-08-24 | 노파르티스 아게 | c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도 |
| WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| AU2017339856B2 (en) * | 2016-10-06 | 2024-09-05 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| WO2018226529A1 (en) * | 2017-06-05 | 2018-12-13 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| TW201932839A (zh) * | 2018-01-12 | 2019-08-16 | 美商格瑞爾公司 | 用於分析病毒核酸之方法 |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| US20220133747A1 (en) | 2018-06-06 | 2022-05-05 | The Regents Of The University Of California | Estrogen receptor inhibitors and uses therof |
| US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
| US12577307B2 (en) * | 2018-10-31 | 2026-03-17 | Genentech, Inc. | Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| DE102019208563B4 (de) | 2019-06-12 | 2026-03-26 | Volkswagen Aktiengesellschaft | Optischer Flüssigkeitssensor und elektrisches System zur optischen Detektion von Flüssigkeiten |
| KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| CA3162311A1 (en) * | 2019-12-20 | 2021-06-24 | Philip E. Brandish | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
| GB2629999B (en) * | 2021-04-21 | 2025-03-26 | Act Therapeutics Ltd | Enhancement of treatment with immunotherapeutic agents |
| KR102779377B1 (ko) | 2022-07-22 | 2025-03-12 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2000044777A1 (en) | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| ATE475431T1 (de) | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK1819358T3 (da) | 2004-11-18 | 2014-10-27 | Imclone Llc | Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| CN104436190A (zh) * | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| KR102130865B1 (ko) | 2012-10-02 | 2020-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물 |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| SI3508502T1 (sl) * | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| ES2716685T3 (es) * | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| WO2015181331A1 (en) * | 2014-05-29 | 2015-12-03 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
| KR20170052569A (ko) * | 2014-07-18 | 2017-05-12 | 어드박시스, 인크. | 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용 |
| US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| SG11201708223QA (en) * | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| DK3858859T3 (da) | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
-
2016
- 2016-07-14 DK DK20214749.2T patent/DK3858859T3/da active
- 2016-07-14 EP EP25203723.9A patent/EP4679094A2/en active Pending
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 RS RS20251179A patent/RS67652B1/sr unknown
- 2016-07-14 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en not_active Revoked
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en not_active Ceased
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 LT LTEP20214749.2T patent/LT3858859T/lt unknown
- 2016-07-14 HR HRP20251434TT patent/HRP20251434T1/hr unknown
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 SM SM20210131T patent/SMT202100131T1/it unknown
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 ES ES20214749T patent/ES3055227T3/es active Active
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja not_active Withdrawn
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Ceased
- 2016-07-14 KR KR1020257014642A patent/KR20250065936A/ko active Pending
- 2016-07-14 EP EP20214749.2A patent/EP3858859B1/en active Active
- 2016-07-14 PT PT202147492T patent/PT3858859T/pt unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 FI FIEP20214749.2T patent/FI3858859T3/fi active
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 SM SM20260008T patent/SMT202600008T1/it unknown
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106098A patent/JP2025138726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522887A5 (enExample) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018514550A5 (enExample) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2018500332A5 (enExample) | ||
| Vici et al. | Emerging biological treatments for uterine cervical carcinoma | |
| JP2019503387A5 (enExample) | ||
| JP2016528195A5 (enExample) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| JP2016525117A5 (enExample) | ||
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2019517512A5 (enExample) | ||
| JP2017534633A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2017537090A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| EP3554515A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019517498A5 (enExample) | ||
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト | |
| JP2019517504A5 (enExample) | ||
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy |